OCGN Strangle Strategy
OCGN (Ocugen, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN (Ocugen, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $497.6M, a beta of 2.31 versus the broader market, a 52-week range of 0.64-2.725, average daily share volume of 9.0M, a public-listing history dating back to 2014, approximately 95 full-time employees. These structural characteristics shape how OCGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.31 indicates OCGN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on OCGN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current OCGN snapshot
As of May 15, 2026, spot at $1.38, ATM IV 102.80%, IV rank 23.32%, expected move 29.47%. The strangle on OCGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on OCGN specifically: OCGN IV at 102.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a OCGN strangle, with a market-implied 1-standard-deviation move of approximately 29.47% (roughly $0.41 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OCGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on OCGN should anchor to the underlying notional of $1.38 per share and to the trader's directional view on OCGN stock.
OCGN strangle setup
The OCGN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OCGN near $1.38, the first option leg uses a $1.45 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OCGN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OCGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.45 | N/A |
| Buy 1 | Put | $1.31 | N/A |
OCGN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
OCGN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on OCGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on OCGN
Strangles on OCGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OCGN chain.
OCGN thesis for this strangle
The market-implied 1-standard-deviation range for OCGN extends from approximately $0.97 on the downside to $1.79 on the upside. A OCGN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current OCGN IV rank near 23.32% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OCGN at 102.80%. As a Healthcare name, OCGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OCGN-specific events.
OCGN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OCGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OCGN alongside the broader basket even when OCGN-specific fundamentals are unchanged. Always rebuild the position from current OCGN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on OCGN?
- A strangle on OCGN is the strangle strategy applied to OCGN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With OCGN stock trading near $1.38, the strikes shown on this page are snapped to the nearest listed OCGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OCGN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the OCGN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 102.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OCGN strangle?
- The breakeven for the OCGN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OCGN market-implied 1-standard-deviation expected move is approximately 29.47%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on OCGN?
- Strangles on OCGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the OCGN chain.
- How does current OCGN implied volatility affect this strangle?
- OCGN ATM IV is at 102.80% with IV rank near 23.32%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.